The Center for Applied Health Sciences, 4302 Allen Road, Suite 120, Stow, OH 44224, USA.
Exercise and Performance Nutrition Laboratory, School of Health Sciences, Lindenwood University, 209 S. Kingshighway, St. Charles, MO 63301, USA.
Nutrients. 2019 Jan 28;11(2):283. doi: 10.3390/nu11020283.
Milk and dairy products are known to contain various bioactives with potential anti-inflammatory and immune modulating effects. Previous research has indicated that milk produced from hyperimmunized cows provided meaningful health benefits to individuals suffering from varying degrees of osteoarthritis and rheumatoid arthritis. To examine the impact of MicroLactin®, a proprietary milk protein concentrate, on joint discomfort and physical function, exercise performance, quality of life and various measures of affect. Non-osteoarthritic men (42.5 ± 8.9 years, 176.7 ± 6.7 cm, 89.9 ± 11.5 kg, 28.8 ± 3.5 kg/m², = 30) and women (46.4 ± 9.6 years, 163.1 ± 8.2 cm, 72.2 ± 13.1 kg, 27.2 ± 5.3 kg/m², = 28) with mild to moderate knee pain during physical activity were randomized in a double-blind, placebo-controlled fashion to consume daily either a placebo (PLA) or MicroLactin® (ML) for a period of 8 weeks. Participants completed a functional capacity test pre and post-supplementation and completed visual analog scales (VAS), a 6-min walking test, WOMAC and profile of mood states (POMS) to assess changes in joint health, discomfort, physical function, exercise performance and affect. Mixed factorial ANOVA was used for all statistical analysis and significance was set at ≤ 0.05. Distance covered in the 6-min walking significantly improved 9% in ML versus 2% in PLA (mean difference: 110 ± 43 m, = 0.012) in addition to 11 WOMAC components and 5 VAS reflective of ML improving joint health, discomfort and joint stability (all < 0.05 vs. PLA). Additionally, ML also improved overall perceptions of neck and back health compared to PLA. Serum and whole blood indicators of clinical safety remained within normal ranges throughout the study. In comparison to placebo, daily doses of MicroLactin yielded improvements in several components of the WOMAC, multiple visual analog scales indicative of joint health and stability, discomfort and pain, as well as significant improvements in distance covered during a 6-min walking test. Supplementation was well tolerated with no significant changes in whole-blood or serum markers of clinical safety.
牛奶和乳制品被认为含有各种具有潜在抗炎和免疫调节作用的生物活性物质。以前的研究表明，来自高免疫奶牛的牛奶为患有不同程度骨关节炎和类风湿关节炎的个体提供了有意义的健康益处。为了研究 MicroLactin®（一种专有的牛奶蛋白浓缩物）对关节不适和身体功能、运动表现、生活质量以及各种情感衡量标准的影响。将患有轻度至中度膝关节疼痛的非骨关节炎男性（42.5 ± 8.9 岁，163.1 ± 8.2 cm，72.2 ± 13.1 kg，27.2 ± 5.3 kg/m²， = 28）和女性（46.4 ± 9.6 岁，176.7 ± 6.7 cm，89.9 ± 11.5 kg，28.8 ± 3.5 kg/m²， = 30）随机分为双盲、安慰剂对照组，每天服用安慰剂（PLA）或 MicroLactin®（ML），为期 8 周。参与者在补充前后完成了一项功能能力测试，并完成了视觉模拟量表（VAS）、6 分钟步行测试、WOMAC 和心境状态问卷（POMS），以评估关节健康、不适、身体功能、运动表现和情感的变化。所有统计分析均采用混合方差分析，显著性水平设置为 ≤ 0.05。6 分钟步行测试的距离显著提高 9%，ML 组为 110 ± 43 m， = 0.012，而 PLA 组为 2%，此外还有 11 个 WOMAC 组成部分和 5 个 VAS 反映了 ML 改善关节健康、不适和关节稳定性（均 < 0.05 与 PLA 相比）。此外，ML 还改善了与 PLA 相比颈部和背部健康的整体认知。整个研究过程中，血清和全血临床安全指标均在正常范围内。与安慰剂相比，MicroLactin 的每日剂量可改善 WOMAC 的多个组成部分、多个反映关节健康和稳定性、不适和疼痛的视觉模拟量表，以及 6 分钟步行测试中覆盖的距离显著提高。补充剂耐受性良好，全血或血清临床安全标志物无显著变化。
